Loading
Mrna / COVID-19 Vaccines / 2019-ncov Vaccine Mrna-1273 · Journal article
Human Vaccines & Immunotherapeutics · May 19, 2026
Reinforces what was already believed, rather than introducing something new.
This literature review synthesized safety data from 27 post-marketing observational studies of mRNA-1273 booster doses (dose 3+) conducted in eight Asian countries. The findings demonstrate that mRNA-1273 boosters were well tolerated across diverse Asian populations, with severe adverse events occurring at low frequency, supporting a favorable safety profile consistent with global data.
Systematic literature review of post-marketing observational studies. Asian populations from South-East Asia and Western-Pacific regions who received mRNA-1273 booster doses. Intervention: mRNA-1273 booster doses (dose 3+). Eight countries: Japan, the Republic of Korea, Australia, Taiwan, Indonesia, Thailand, the Philippines, and Singapore.
886 records were screened, with 27 studies from eight countries meeting inclusion criteria mRNA-1273 boosters were well tolerated across studies, with severe AEs occurring at low frequency Studies included populations from Japan, the Republic of Korea, Australia, Taiwan, Indonesia, Thailand, the Philippines, and Singapore
Specific adverse event incidence rates and severity grades are not quantified in the text provided Long-term safety data beyond the study period are not available and require ongoing monitoring
The consistent safety profile across diverse Asian populations supports continued use of mRNA-1273 boosters in national immunization programs targeting high-risk groups. Clinicians can use this evidence to inform vaccine counseling and address patient safety concerns regarding COVID-19 booster doses in Asian populations.
Literature review of 27 post-marketing observational studies across eight Asian countries confirms favorable safety profile of mRNA-1273 boosters with low severe adverse event rates.
As stated by the source record.
Quoted from the source exactly as published.
The consistent safety profile across diverse Asian populations supports continued use of mRNA-1273 boosters in national immunization programs targeting high-risk groups. Clinicians can use this evidence to inform vaccine counseling and address patient safety concerns regarding COVID-19 booster doses in Asian populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Real-world data on the safety of COVID-19 booster doses in Asian populations are needed to inform national immunization programs. The safety profile of mRNA-1273 (Moderna, Inc.) was evaluated using post-marketing observational data. PubMed and EMBASE were searched on June 30, 2025, for studies meeting the following predefined criteria: observational design, adverse events (AEs), mRNA-1273 boosters (dose 3+), and population data from the South-East Asia and Western-Pacific regions. Data on study characteristics, and AE incidence and severity, were extracted. Of 886 records screened, 27 studies from eight countries (Japan, the Republic of Korea, Australia, Taiwan, Indonesia, Thailand, the Philippines, and Singapore) met the inclusion criteria. Across studies, mRNA-1273 boosters were well tolerated, with severe AEs occurring at low frequency. Based on the included observational studies, these findings support the favorable safety profile of mRNA-1273 boosters in Asian populations. Long-term safety monitoring is needed to guide public-health responses to evolving SARS-CoV-2 variants.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.